Requests · The University of Texas Medical Branch at Galveston

Southeast Texas Gene Therapy & Precision Medicine Center

Priority 1 · one of 3 items in the The University of Texas Medical Branch at Galveston's request for 2028-29 · The item begins on page 106 of the request

This is a request, not an appropriation.

What is asked

20282029Two years
All funds$5,000,000$5,000,000$10,000,000
Of which general revenue and general revenue-dedicated $5,000,000$5,000,000$10,000,000
Positions (full-time equivalents) 5.05.0

How it would be financed

Method of financing, as the request prints it20282029
1 General Revenue Fund$5,000,000$5,000,000
Total, as the request prints it$5,000,000$5,000,000

Where it would land

The strategies this item would add to, numbered as the request numbers them, beside what each is appropriated in the current budget (2026-27 Act). One column is an appropriation and the other a request made on top of a base request not shown here, so the two are not subtracted.

Strategy Asked 2028Asked 2029Positions Appropriated 2026Appropriated 2027
05-04-01 Exceptional Item Request $5,000,000$5,000,0005.0No strategy matched in the current budget

A strategy is matched by its name. Where none is matched, the strategy may be new, or may be in the current budget under a different name.

After 2029

The agency's estimate203020312032Three years
All funds$5,000,000$5,000,000$5,000,000$15,000,000

In the agency's words: Expectation to continue this project at the full amount.

The agency's justification

UTMB’s Gene Therapy Program is dedicated to the patient’s health, from initial genetic counseling, to ensuring safe and effective use of the therapy, to post-treatment care. There have been 17 patients treated with gene therapies at UTMB, from places across Texas. UTMB looks to grow our clinical and research abilities, meeting the needs of the moment to continue and advance our service of the Texas patient population. This initiative would recruit and retain dedicated health care providers, genetic experts, and researchers, while upgrading our care infrastructure and equipment. UTMB’s approach is multi-disciplinary, with robust expertise (Genetics, Dermatology, Cardiology, ENT, Neurology, and Anesthesia), facilitating the safe use of innovative treatments. UTMB’s medical genetics team is small, with no individuals staffed for 100% allocation to gene therapy clinical work (current focus is around 10% of clinical time for providers). State funding would allow investment in specialized health care providers (physicians, nurses), with established operational support, to facilitate gene therapies, alongside recruitment for additional, needed roles, such as research. Additional funding is necessary to build a medical genetics research arm, to allow clinical trial ability at our institution. This will allow UTMB to test emerging gene therapies and perfect delivery methods. UTMB’s Sealy Diagnostic Center utilizes precision medicine to provide innovative and advanced diagnostic services. The Center performs genomic analysis to better select medications or adjust dose to prevent toxicity or failure of therapy. Pathologists also use AI-assisted technologies to diagnose critical health conditions, including cardiovascular disease, bleeding and clotting disorders, chronic conditions and prostate cancer.

102 of 159 Allowing UTMB to continue offering more effective and innovative treatment options, as more gene therapies and diagnostics become available for patients, will save lives.

External and internal factors

UTMB is among the few centers in Texas offering FDA-approved gene therapies and specialty genetic drugs, for conditions including Duchenne/Becker Muscular Dystrophy (Elevidys), Hemophilia A (Roctavian), Recessive Dystrophic Epidermolysis Bullosa (Zevaskyn), and Spinal Muscle Atrophy (Zolgensma).UTMB is also home to the Sealy Diagnostic Center, which develops innovative diagnostic services, such as personalized genomic analysis, to better select medications or adjust doses to prevent toxicity or failure of a therapy. As more gene therapies become available for patients, UTMB’s specially equipped clinical care teams will uniquely position the institution to deepen clinical offerings to the Texas population.

As marked in the request